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Abstract  
Background 
Although sevoflurane (Sevo) had been shown to ameliorate post-transplant injury in various organs, 
data available are inconsistent, particularly in the context of lung transplantation (Tx). We here 
investigated if preconditioning by Sevo can protect from post-transplant injury regarding both, 
primary graft dysfunction (PGD) and acute rejection (AR) after experimental lung Tx, thereby 
focusing on two important clinical outcome parameters.  
Materials and Methods 
Three experimental approaches were employed: (I) BALB/c mice were preconditioned for 2 hours 
with Sevo or a fentanyl cocktail (Control) (n=10), (II) syngeneic mouse lung Tx (C57BL/6) with a 
Sevo-preconditioned graft followed by 18 hours storage to mimic PGD (Syn-Tx, n=12) vs. controls 
(fentanyl cocktail), and (III) allogeneic Tx (BALB/c, donor; C57BL/6, recipient) to mimic AR (Allo-
Tx, n=12) vs. controls (fentanyl cocktail). Syn-Tx grafts were harvested on day 1, Allo-Tx grafts on 
day 3 and analyzed for histology, immunohistochemistry, blood gas analysis, and inflammatory 
cytokines (ELISA or RT-PCR).  
Results 
Evaluating the preconditioning effect of Sevo only showed significantly better oxygenation (p=0.03) 
and a tendency towards lower levels of lung tissue mRNA for TNF-α. In Syn-Tx receipients, the Sevo 
group had histologically a tendency towards an attenuation of PGD and showed significantly lower 
levels of IL-6 (p=0.01) in plasma, but higher levels of IL-10 (p<0.01) in lungs. Allo-Tx grafts in Sevo 
Tx recipients showed attenuated AR with histologically significantly lower rejection scores (p=0.03), 
fewer classical macrophages (F4/80+; p<0.01), but more anti-inflammatory activated macrophages 
(M2, CD206+; p<0.01). Functionally, the Sevo group had a tendency towards improved oxygenation. 
Conclusions 
We demonstrated that Sevo preconditioning has protective effects on lung transplants in both, PGD 
and AR. The observed amelioration may be attributed to suppressed inflammatory cytokines during 
PGD and the induction alternatively activated macrophages during AR. These promising data could 
set the base for employing Sevo preconditioning in donor lungs for a human trial.
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Introduction 
Lung transplantation (Tx) has been established for several decades as a therapeutic option for end-
stage pulmonary disease patients. In spite of recent developments including surgery, 
immunosuppressive and perioperative management (1, 2), primary graft dysfunction (PGD) and acute 
rejection (AR) following lung Tx are still a major hurdle on the way to long term graft acceptance (3). 
PGD and AR are not only responsible for early transplant morbidity and mortality (4), these two 
pathologic entities contribute to the development of chronic lung allograft dysfunction, the major 
impediment to long-term survival of lung transplanted patients (5).  
Preconditioning by sevoflurane (Sevo), a clinically frequently used volatile anesthetic, has been shown 
to attenuate I/R injury and also AR in several organs, such as liver, kidney, heart and lung (6-9) 
through reducing inflammatory cytokines (10, 11), chemokines (12) and adhesion molecules (13). A 
possible mechanism responsible for this beneficial effect has been attributed to the homeostasis of 
adenosine triphosphate (ATP) in mitochondria with slower calcium influx (14) and antioxidant activity 
(11, 13). Some data exist for Sevo preconditioning in lung Tx, but they are largely limited to the 
analysis of PGD, showing a decrease of the inflammatory response and oxidative stress of I/R injury 
(9, 15). Others demonstrated the efficacy of volatile anesthetics to attenuate I/R injury in an isolated 
lung model without Tx procedure (16, 17).  
We therefore investigated here if Sevo preconditioning of the donor graft might have protective effects 
on both, PGD and AR. To this end, we applied different experimental set-ups to best mimic the human 
post-transplant setting by employing syngeneic mouse lung Tx for PGD, and allogeneic Tx for AR. 
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Materials and Methods 
Mice 
Specific pathogen-free inbred male mice, strain C57BL/6 (H2b) and BALB/c (H2d) (Charles River 
Laboratories, Sulzfeld, Germany), weighing 27–30 g were used. Animals received adequate care in 
strict accordance with the Principles of Laboratory Animal Care (National Institutes of Health 
Publication No. 85-23, promulgated in 1985, most recently revised in 1996). The study was approved 
by the local veterinary ethical committee under the study number 45/2014. 
 
Experimental groups for the induction of PGD and AR 
To investigate the impact of Sevo on donor preconditioning only, we performed preconditioning of 
Sevo (3% of Sevo for 2 hours) on the donor organ without Tx. In all other experiments, the orthotopic 
single left lung transplantation was performed as we described in detail previously (2, 18).  
Two groups of Tx were formed: (I) syngeneic Tx (Syn-Tx, C57BL/6 →C57BL/6) and (II) allogeneic 
Tx (Allo-Tx, BALB/c → C57BL/6). Both groups, Syn-Tx as well as Allo-Tx were further subdivided 
into one donor group that received a Sevo preconditioning (3% of Sevo for 2 hours), and another 
donor group that received ip.-narcosis, in order to be able to discriminate the effect of Sevo 
preconditioning. All control mice received an ip.-narcosis by applying a volume of 2 μl/g of an 
anesthetic cocktail composed of 1 ml of 0.05% fentanyl, 5 mg of midazolam, 0.5 mg of medetomidin 
and 0.5 ml of 0.9% saline. The narcosis was maintained for 2 hours with 0.5 μl/g of 0.016% fentanyl 
administered at every 40 minutes after the induction and terminated by giving a cocktail of naloxon, 
flumazenil and atipamezol. All recipient mice received this type of ip.-narcosis without the use of 
Sevo. Syn-Tx mice underwent an 18 hour cold ischemia time prio to Tx, as we described before (19). 
Recipient mice in the Syn-Tx group were sacrifized at day 1, and in the Allo-Tx group at day 3 after 
Tx.  
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Graft harvest and assessment 
Sacrifice of Tx recipient mice were performed as previously described (2, 18). 500μl of whole blood 
was aspirated from the inferior vena cava for assessment of cytokines, and 100μl of arterial blood was 
aspired from the descending aorta for blood gas analysis. Thereafter, lungs were flushed with 2 ml of 
0.9% normal saline solution at a pressure of 10 cm H2O via the pulmonary artery, and organs were 
subsequently removed. Harvested lungs were washed in PBS and snap frozen in liquid nitrogen and 
stored at -80 °C until performance of the assays. 
 
Histology and pathological grading 
Transplanted lungs from each group were harvested, fixed in 4% phosphate buffered formalin, cut and 
embedded in paraffin. Sections of 4 μm thickness were cut and stained for hematoxylin & eosin (HE). 
These sections were graded for rejection pathology using the standard criteria (20) and assessed by 
three different investigators in a blinded fashion.  
 
Immunohistochemistry  
Transplanted lungs were fixed in formalin (4%), paraffin embedded, and processed for 
immunohistochemistry (IHC). IHC staining was performed on BondMax with Refine HRP-Kit 
DS9800 (Leica Biosystems, Muttenz, Switzerland) according to the manufacturers’ guidelines. 
Primary antibodies were rabbit anti-CD3 mAb (RMAB005, Diagnostic Biosystems, Pleasanton, USA), 
rat anti F4/80 mAb (T-1006, BMA Biomedicals, Augst, Switzerland), rat anti-CD45R (B220) (RA3-
6B2, BD Pharmingen, Allschwil, Switzerland), rabbit anti-neutrophil elastase polyclonal antibody 
(ab21595, Abcam, Cambridge, UK) and rabbit anti-CD206 mAb (18704-1-AP, Proteintech, Chicago, 
USA). The number of positive cells in the perivascular and peribronchiolar areas was counted. Vessels 
or airways with the diameter of 150μm were the target for counting. Five sites on each section were 
chosen. Immuno-stained sections were assessed by three different investigators in a blinded fashion.  
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Oxygenation of lung transplants 
PaO2/FiO2 ratio in the transplanted animal was taken from the abdominal aorta (100 μl) for blood gas 
analysis and electrolyte measurement test (Epocal Inc., Ottawa, ON Canada), in order to evaluate the 
function of the graft after lung Tx. 
 
Quantitative real-time PCR  
Total RNA was extracted by mirVana Paris kit (Ambion, Thermo Fisher Scientific, Waltham, MA) 
following the manufacturer's instructions. Five micrograms of RNA were used for reverse 
transcription by ThermoScript reverse transcription-PCR (RT-PCR) System (Invitrogen, Thermo 
Fisher Scientific) yielding cDNA template. Quantitative real-time PCR amplification and data analysis 
were performed using 7500 Fast Real-Time PCR System (Applied Biosystems, Thermo Fisher 
Scientific). Taq Man gene expression assays were used to quantify mRNA expression of the respective 
genes. mRNA expression levels of each sample were normalized to 18S RNA (Taq Man rRNA control 
reagents; Applied Biosystems). All mRNA expression data was calculated as fold change from naïve 
animal tissues. 
 
Quantification of cytokines (ELISA) 
Lung samples were homogenized in lysis buffer containing a protease inhibitor cocktail (Roche 
Diagnostics GmbH, Mannheim, Germany), phosphatase inhibitor cocktail 3, 50 mM Tris, 150 mM 
NaCl, 5 mM EDTA, and 0.5 % NP-40 (Sigma-Aldrich, St. Louis, USA). The concentration levels of 
IL-6, IL-10 and TNF-α in mouse plasma and lung homogenates were assayed by ELISA using the 
paired Abs for capture and detection according to the manufacturer’s instructions (R&D Systems, 
Santa Cruz, USA). 
 
Statistics 
Data were presented as means ± standard deviation. Groups were compared with the Student t-test for 
unpaired samples using Prism 5 (GraphPad Software, San Diego, CA, USA). A two-sided p-value 
<0.05 was considered as statistically significant. 
Sevoflurane protects lung transplants      150117 REVISED 
 
8 
 
Results 
Sevoflurane preconditioning improved oxygenation in donor lungs 
In order to analyze the effect of Sevo on the donor organ only, we preconditioned a donor lung in 
animals with Sevo n=5) and without Sevo (control, n=5). PaO2/FiO2 ratio in the Sevo group was 
significantly higher than the control group (Fig. 1a) (p=0.030). RT-PCR of inflammatory cytokines 
showed a relative suppression of the production of TNF-α in the Sevo group (Fig 1b) (p=0.20).   
 
Sevoflurane preconditioning attenuated PGD histologic injury in Syn-Tx. 
Histologically, transplanted lungs in the control group (n=6) showed severe PGD features 
characterized by diffuse alveolar septal thickening with edema and neutrophilic infiltrates (Fig 2A) 
when compared to, the Sevo group which showed less severe damage of a PGD pathology (Fig 2B). 
 
Sevoflurane reduced levels of IL-6 and enhanced levels of IL-10 in Syn-Tx 
We performed ELISA to analyze levels of the pro-inflammatory cytokine IL-6 and the anti-
inflammatory cytokine within recipient transplants. Levels of IL-6 in the Sevo group revealed 
significantly lower levels in plasma (Fig 3A) (p=0.012) and relatively lower levels in lung tissue (Fig 
3B) (p=0.15) when compared to the control group. In contrast, levels of IL-10 in the Sevo group were 
significantly higher in lung tissue (Fig 3D) (p=0.002) and relatively higher in plasma (Fig 3C) 
(p=0.15).  
 
Sevoflurane did not improve oxygenation in Syn-Tx 
PaO2/FiO2 ratios in both groups on day 1 were comparable among animals (Control 389±99 versus 
Sevo 396±74; p=0.90).  
 
Sevoflurane preconditioning attenuated AR in Allo-Tx. 
Allogeneic orthotopic single-lung Tx was performed using a MHC class I and II fully mismatch 
combination strain between C57BL/6 and BALB/c mice in the Sevo (n=6) and the control group (n=6).  
Histology of control lung transplants, harvested on day 3 (n=6) showed severe AR pathology 
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characterized by perivascular and peribronchiolar mononuclear infiltration (Fig 4A). In contrast, the 
Sevo group had less infiltrates (Fig 4B). According to the rejection score (ISHLT guidelines, (20)), the 
Sevo group had a significantly reduced acute rejection score when compared to controls (Fig 4C) 
(p=0.030). 
 
Sevoflurane preconditioning induced increased numbers of M2 macrophages in Allo-Tx 
In order to identify a putative cell population that could play a protective role upon Sevo 
preconditioning, we analyzed for the anti-inflammatory subtype of macrophages, M2. To do so, we 
performed IHC staining using antibodies for F4/80+ (total macrophage), CD206+ (alternative 
activated M2 macrophage). Also, CD3+ (pan-T cell marker), B220+ (B cell marker) and Neutrophil 
elastase (neutrophil) were stained to further dissect cell populations in allo Tx recipients. Figure 5 
shows representative IHC sections of F4/80+ and CD206+. F4/80+ cells were enhanced in controls 
compared to the Sevo group (Fig 5A, B). Also, the number of F4/80+ cells in the perivascular and 
peribronchiolar areas were significantly higher (Fig 5C) (p=0.001). The number of CD206+ 
macrophages was higher in the Sevo group (Fig 5F) (p=0.003) but there were less CD206+ 
macrophages in controls (Fig 5D, 5E). T cells, B cells and neutrophils, were not significantly different 
among animals. 
 
Sevoflurane preconditioning improved oxygenation in Allo-Tx  
There was a tendency of PaO2/FiO2 ratio improvement in the Sevo group when compared to controls 
though without significant difference (Fig. 6) (p=0.16). 
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Discussion 
The efficacy of Sevoflurane preconditioning has been investigated in the context of solid organ 
transplantation (6, 7, 9). However, results obtained in clinical trials in liver and kidney transplantation 
turned out to be inconsistent (21, 22). With regard to lung Tx, there is virtually no data, neither on the 
impact of Sevo in lung transplant recipients nor on Sevo in donor organs. Our primary aim here was 
therefore to evaluate the impact of donor organ preconditioning on PGD and AR by Sevo. We found 
that Sevo preconditioning of the donor organ attenuates PGD and AR histology and improved 
oxygenation and upregulated protectiveM2 macrophages with a promotion of anti-inflammatory 
activity, therefore displaying protecting effects on lung Tx outcome.  
During donor preconditioning, we could observe an improvement of oxygenation with a relative 
suppression of the inflammatory cytokine TNF-α. Indeed, our data were supported by previous reports 
about the efficacy of volatile anesthetics in a mouse model of ventilator-induced lung injury (11, 23).  
In this context, TNF-α was proved to be sensitive marker for acute lung injury (24). Only 
preconditioning of lung organs by Sevo without Tx showed a trend towards suppression of 
inflammation and thus gives a hint towards a beneficial effect of Sevo.   
In order to stimulate and ensure robust I/R injury and thus PGD, we used the syngeneic Tx setting 
employing 18 hours ischemia. Here, a strong impact by Sevo preconditioning could be observed 
reflected by an improvement of PGD histological injury, the suppression of the inflammatory cytokine 
IL-6 and the promotion of the immunosuppressive cytokine IL-10. Previous data showed a rapid 
elevation of IL-6 level after reperfusion and the association to the severity of reperfusion injury in the 
context of PGD (25). These data are corroborated by others, e.g. Casanova et al. reported the efficacy 
of Sevo preconditioning in an auto-transplant pig model showing a decrease of oxidative stress marker, 
pro-inflammatory mediators, chemokines and adhesion molecules (9, 15). Also, a study of Rancan et 
al. also in lung auto-transplant in pigs showed decreased inflammatory cytokine and chemokine in 
liver (26).   
While there is some evidence of an amelioration of PGD in syngeneic lung Tx, no reports are available 
so far on allo-Tx in the context of Sevo preconditioning. We showed that Sevo preconditioning 
attenuates AR damage histologically and upregulates M2 macrophages, cells that bear anti-
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inflammatory activity. Evidence suggests that 5' adenosine monophosphate-activated protein kinase 
(AMPK) plays an important role in M2 macrophage polarization (27, 28).  AMPK, an important 
sensor and regulator of cellular energy status, is activated in response to ischemic stress and is 
implicated in ischemic preconditioning (29). Specifically this activation of AMPK can also be induced 
by Sevo as shown in a sevoflurane-induced cardioprotection model (30). These data could be a hint to 
how alternative macrophages can act to protect the transplant through Sevo. 
Shortcomings of this study are obvious: functional data of oxygenation obtained here were 
heterogeneous among types of experiments. This can be explained by the blood sampling procedure. 
We chose for taking whole arterial blood samples via the abdominal descending aorta without 
clamping the right hilum due to sudden death by the animal when occluding the right lung and only 
evaluating the left lungs oxygenation. We consider this as an indirect evaluation of the functionality of 
the Tx lung, however, it shows a trend towards an improvement of functionality. Only in the Allo-Tx 
group, lung injury on the left side in the control group could have been compensated by the right lung 
ventilation. Another limitation of this study was cardio-dynamic differences between volatile 
anesthetics and injection anesthetics of fentanyl, midazolam and medetomidine that we used for 
controls (31, 32). Although the iv.-narcosis is widely used in the clinical setting and qualifies well for 
this control group (equivalent to ip.-narcosis), it limits the comparability to a clinical setting due to 
interference with inflammatory parameters analyzed.  
Sevo is already routinely used in many centers not only in North America but also worldwide for the 
recipient lung Tx procedure, however, there is no systematic analysis available on a beneficial effect 
of Sevo on lung transplant outcome in these recipients. Also, Sevo preconditioning in donor lung 
organs has not been performed yet in order to analyze an additional beneficial outcome in lung 
transplanted patients. Some evidence towards a positive effect of Sevo preconditioning in human liver 
transplants exists, but overall evidence remains scarce.  
Moreover, studies available on transplant outcome and Sevo preconditioning are limited to the 
analysis of the impact on PGD, but there is no experimental work investigating AR. We could 
therefore provide here the first evidence of a beneficial effect of Sevo donor organ preconditioning on 
post lung transplant outcome in PGD and AR.  
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Clinically, Sevo preconditioning in a pre-transplant setting would be well doable without much 
changing the pre-operative set up. Also, a suitable possibility for preconditioning would be the use of 
the ex vivo lung perfusion system (1). If Sevo preconditioning positively influences lung transplant 
outcome, this measure would be a valuable addition to Sevo-narcosis in lung transplant recipients.  
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Figure legends 
Figure 1 
(A) Blood gas analyses were measured on a donor graft after 2 hours of Sevo preconditioning. 
PaO2/FiO2 ratio in the Sevo organs were significantly higher than in controls (p=0.030). (B) RT-PCR 
on lung homogenate samples showed a relative suppression of TNF-α in the Sevo group (p=0.20). 
Asterisk indicates significant differences.  
 
Figure 2 
Representative HE pathology of syngeneic lung Tx on day 1: (A) Grafts in the control group showed a 
typical pathology of PGD with diffuse septal thickening, edema and cell infiltrations. (B) Graft in the 
Sevo group showed attenuated PGD pathology when compared to controls. 
 
Figure 3 
Cytokines in Syn-Tx were measured by ELISA. (A) Levels of IL-6 in plasma in the Sevo group were 
significantly lower than in controls (p=0.012). (B) There was a tendency towards a suppression of IL-6 
in lung in the Sevo group (p=0.15). (C) Also, there was a tendency towards an enhancment of IL-10 in 
plasma in the Sevo group (p=0.15). (D) Levels of IL-10 in lungs in the Sevo group were significantly 
higher than in controls (p=0.002). Asterisk indicates significant differences. 
 
Figure 4 
Representative H&E pathology of Allo-Tx recipients on day 5: (A) Grafts in controls showed a typical 
pathology of acute rejection with perivascular mononuclear infiltration. (B) Grafts in the Sevo group 
showed an attenuation of AR compared to controls (C) The rejection score showed a significant 
difference between the two groups (p=0.030). Asterisk indicates significant differences. 
 
Figure 5  
Representative immunohistochemical analyses of Allo-Tx mice on day 5: F4/80 staining (total 
macrophages) (A, B) and CD206 staining (anti-inflammatory M2 macrophage) (D, E) of the control 
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(A, D) and the Sevo group (B, E). There were less F4/80 positive cells in controls compared to the 
Sevo group (p=0.001) (C), while more CD206 positive cells were detected (p=0.003) (D). Asterisk 
indicates significant differences. 
 
Figure 6 
PaO2/FiO2 ratio in the Allo-Tx on day 5 had a tendency toward the improvement in the sevo group 
compared to controls (p=0.16).  
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